Despite the success of immunotherapy and cell therapy in rare cancers, solid tumors such as lung and colon cancers have yet to benefit from these treatments. 7 Hills Pharma is addressing this issue by developing cost-effective technologies that modulate the immune system to increase the effectiveness of immune checkpoint blockade, adoptive cell therapy, and cord blood transplant. Their platform improves the antitumor activity of numerous emerging cell-based immunotherapies, making it possible for people to access cost-effective and safe therapeutics that increase the effectiveness of emerging immune-oncology drugs and infectious disease vaccines.